These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30360647)

  • 21. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
    Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
    Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.
    Trujillo JM; Roberts M; Dex T; Chao J; White J; LaSalle J
    Diabetes Obes Metab; 2018 Nov; 20(11):2690-2694. PubMed ID: 29923298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.
    Frias JP; Dex T; Roberts M; Kaplan A
    Diabetes Ther; 2019 Feb; 10(1):21-33. PubMed ID: 30539523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
    Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
    Yabe D; Iizuka K; Baxter M; Watanabe D; Kaneto H
    J Diabetes Investig; 2021 Nov; 12(11):1992-2001. PubMed ID: 33945227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
    Guo X; Yang W; Zhang J; Dong X; Liu M; Gu S; Lauand F; Li L; Huang Q; Kang L; Souhami E
    Diabetes Obes Metab; 2023 Jul; 25(7):2005-2011. PubMed ID: 36999231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
    Yale JF; Roborel de Climens A; Aggarwal N; Dex T; Gerstein HC; Harris S; Hramiak I; Stewart J; Leiter LA
    Diabetes Ther; 2023 Feb; 14(2):377-386. PubMed ID: 36574199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
    Davies MJ; Russell-Jones D; Barber TM; Lavalle-González FJ; Galstyan GR; Zhu D; Baxter M; Dessapt-Baradez C; McCrimmon RJ
    Diabetes Obes Metab; 2019 Aug; 21(8):1967-1972. PubMed ID: 31124299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
    Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
    Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
    Bajaj HS; Chu L; Bansal N; Brown RE; Dhillon G; Gupta R; Bhela JS; Padda JK; Khandwala H; Venn K; Aronson R
    Can J Diabetes; 2022 Jul; 46(5):495-502. PubMed ID: 35752566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
    Niemoeller E; Souhami E; Wu Y; Jensen KH
    Diabetes Ther; 2018 Feb; 9(1):373-382. PubMed ID: 29143919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
    Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
    BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
    Sugimoto DH; Dex T; Stager W; Aroda VR
    Diabetes Obes Metab; 2018 Nov; 20(11):2680-2684. PubMed ID: 29923361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
    Jammah AA
    Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
    Yang W; Guo X; Lauand F; Li L; Fang H; Du Q; Kang L
    Diabetes Obes Metab; 2024 Apr; 26(4):1197-1206. PubMed ID: 38172083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
    Iizuka K; Baxter M; Watanabe D; Yabe D
    Diabetes Obes Metab; 2021 Dec; 23(12):2795-2803. PubMed ID: 34472693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.